Dasiglucagon hydrochloride
As of the edition of 20 October 2026, Dasiglucagon hydrochloride is a protein: marketed, first approved in 2021 (US); acts on GCGR; US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Protein
- Brand name
- Zegalogue
- First approved
- 22 March 2021 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Zealand Pharma
US protection
US protection ends in 2035.
The last listed US drug-substance patent ends in 2035. The application that gives this date is held by Zealand Pharma.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product6 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 6 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Dasiglucagon hydrochloride.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GCGR | Glucagon receptor | P47871 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Zealand Pharma | Acquired holder | 2021 to now |